alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) antagonists: from bench to bedside.
Mattes
Henri
H
Novartis Pharma AG, Werk Klybeck, WKL-122-241 Postfach, CH-4002 Basel, Switzerland. henri.mattes@novartis.com
Carcache
David
D
Kalkman
Hans O
HO
Koller
Manuel
M
D000700:Analgesics / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D000927:Anticonvulsants / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004353:Drug Evaluation, Preclinical; D006801:Humans; D018696:Neuroprotective Agents / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D021122:Protein Subunits / Q000037:antagonists & inhibitors / Q000235:genetics / Q000502:physiology; D018091:Receptors, AMPA / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000502:physiology
D000700:Analgesics; D000927:Anticonvulsants; D014150:Antipsychotic Agents; D018696:Neuroprotective Agents; D021122:Protein Subunits; D018091:Receptors, AMPA